{"id":6548,"date":"2013-09-26T18:02:07","date_gmt":"2013-09-26T23:02:07","guid":{"rendered":"https:\/\/www.bad-drug.net\/?p=6548"},"modified":"2017-09-19T14:52:26","modified_gmt":"2017-09-19T19:52:26","slug":"onglyza-study-boosts-stock","status":"publish","type":"post","link":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock","title":{"rendered":"Onglyza Study Boosts Stock"},"content":{"rendered":"<p>Onglyza is a prescription drug used to treat type II diabetes. It is considered a DPP-4 inhibitor that diabetics use to help regulate their blood pressure. It is also known as &#8220;incretin mimetics&#8221;, meaning it is a chemical that acts as an insulin-copycat in order to stimulate the pancreas to produce more insulin. It is recommended that the person taking Onglyza eats a healthy diet and exercises to improve blood sugar levels. AstraZeneca is the pharmaceutical company that produces Onglyza. In addition, \u00a0AstraZeneca has a collaboration agreement with Bristol-Myers Squibb Company for the drug.<\/p>\n<p>AstraZeneca has been presented with evidence that Onglyza can cause pancreatitis and even pancreatic cancer.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-6550 alignright\" alt=\"Onglyza\" src=\"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/Onglyza.jpg\" width=\"259\" height=\"194\" \/><\/p>\n<p>The recent study could be the reason for AstraZeneca&#8217;s stock growth. Onglyza revenues as recorded by AstraZeneca were $102 million in the second quarter of 2013, reflecting an increase of 28% over the year-ago period.<\/p>\n<h2>AstraZeneca&#8217;s Onglyza Study<\/h2>\n<p>AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. The study was a randomized, double-blind, placebo-controlled study that evaluated Onglyza in patients with a history of cardiovascular disease or multiple risk factors.<\/p>\n<p>The study concluded that the primary composite endpoint of cardiovascular death, non-fatal MI or non-fatal ischemic stroke occurred in 7.3% of the patients in the Onglyza arm as compared to 7.2% in the placebo arm.<\/p>\n<p><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script><br \/>\n<ins class=\"adsbygoogle\"\n     style=\"display:block; text-align:center;\"\n     data-ad-layout=\"in-article\"\n     data-ad-format=\"fluid\"\n     data-ad-client=\"ca-pub-6229368185227371\"\n     data-ad-slot=\"2635120758\"><\/ins><br \/>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><\/p>\n<p>Onglyza did not present itself to be exceptionally superior to the placebo with respect to an endpoint that including cardiovascular death, non-fatal myocardial infarction (:MI) or non-fatal ischemic stroke. However, the drug met the primary safety objective of non inferiority to placebo for the same composite endpoint.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Onglyza is a prescription drug used to treat type II diabetes. It is considered a DPP-4 inhibitor that diabetics use to help regulate their blood pressure. It is also known as &#8220;incretin mimetics&#8221;, meaning it is a chemical that acts as an insulin-copycat in order to stimulate the pancreas to produce more insulin. It is recommended that the person taking Onglyza eats a healthy diet and exercises to improve blood sugar levels. AstraZeneca is the pharmaceutical company that produces Onglyza. In addition, \u00a0AstraZeneca has a collaboration agreement with Bristol-Myers Squibb Company for the drug. AstraZeneca has been presented with evidence that Onglyza can cause pancreatitis and even pancreatic cancer. The recent study could be the reason for AstraZeneca&#8217;s stock growth. Onglyza revenues as recorded by AstraZeneca were $102 million in&#8230;  <a href=\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock\" ><img decoding=\"async\" alt=\"Read More\" src=\"http:\/\/www.bad-drug.net\/wp-content\/themes\/baddrug\/images\/readmore.png\" class=\"lbdreadmore\"><\/a><\/p>\n","protected":false},"author":991,"featured_media":6549,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[4],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Onglyza Study Boosts Stock<\/title>\n<meta name=\"description\" content=\"AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. Read more about how it may have boosted stock value\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onglyza Study Boosts Stock\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. Read more about how it may have boosted stock value\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock\" \/>\n<meta property=\"og:site_name\" content=\"Bad Drug\" \/>\n<meta property=\"article:published_time\" content=\"2013-09-26T23:02:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-09-19T19:52:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"168\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"celeste garza\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"celeste garza\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock\",\"url\":\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock\",\"name\":\"Onglyza Study Boosts Stock\",\"isPartOf\":{\"@id\":\"https:\/\/www.bad-drug.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg\",\"datePublished\":\"2013-09-26T23:02:07+00:00\",\"dateModified\":\"2017-09-19T19:52:26+00:00\",\"author\":{\"@id\":\"https:\/\/www.bad-drug.net\/#\/schema\/person\/b9e2bb4f1f88736f6de722b47c9efe42\"},\"description\":\"AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. Read more about how it may have boosted stock value\",\"breadcrumb\":{\"@id\":\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#primaryimage\",\"url\":\"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg\",\"contentUrl\":\"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg\",\"width\":300,\"height\":168,\"caption\":\"AstraZeneca\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Bad Drug\",\"item\":\"https:\/\/www.bad-drug.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onglyza Study Boosts Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bad-drug.net\/#website\",\"url\":\"https:\/\/www.bad-drug.net\/\",\"name\":\"Bad Drug\",\"description\":\"Your Resource for Adverse Reactions and Drug Recalls\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bad-drug.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bad-drug.net\/#\/schema\/person\/b9e2bb4f1f88736f6de722b47c9efe42\",\"name\":\"celeste garza\",\"url\":\"https:\/\/www.bad-drug.net\/author\/celesteg\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onglyza Study Boosts Stock","description":"AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. Read more about how it may have boosted stock value","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock","og_locale":"en_US","og_type":"article","og_title":"Onglyza Study Boosts Stock","og_description":"AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. Read more about how it may have boosted stock value","og_url":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock","og_site_name":"Bad Drug","article_published_time":"2013-09-26T23:02:07+00:00","article_modified_time":"2017-09-19T19:52:26+00:00","og_image":[{"width":300,"height":168,"url":"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg","type":"image\/jpeg"}],"author":"celeste garza","twitter_misc":{"Written by":"celeste garza","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock","url":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock","name":"Onglyza Study Boosts Stock","isPartOf":{"@id":"https:\/\/www.bad-drug.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#primaryimage"},"image":{"@id":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#primaryimage"},"thumbnailUrl":"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg","datePublished":"2013-09-26T23:02:07+00:00","dateModified":"2017-09-19T19:52:26+00:00","author":{"@id":"https:\/\/www.bad-drug.net\/#\/schema\/person\/b9e2bb4f1f88736f6de722b47c9efe42"},"description":"AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. Read more about how it may have boosted stock value","breadcrumb":{"@id":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#primaryimage","url":"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg","contentUrl":"https:\/\/www.bad-drug.net\/wp-content\/uploads\/2013\/09\/download.jpg","width":300,"height":168,"caption":"AstraZeneca"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bad-drug.net\/bad-drug-blog\/onglyza-study-boosts-stock#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Bad Drug","item":"https:\/\/www.bad-drug.net\/"},{"@type":"ListItem","position":2,"name":"Onglyza Study Boosts Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.bad-drug.net\/#website","url":"https:\/\/www.bad-drug.net\/","name":"Bad Drug","description":"Your Resource for Adverse Reactions and Drug Recalls","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bad-drug.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bad-drug.net\/#\/schema\/person\/b9e2bb4f1f88736f6de722b47c9efe42","name":"celeste garza","url":"https:\/\/www.bad-drug.net\/author\/celesteg"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/posts\/6548"}],"collection":[{"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/users\/991"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/comments?post=6548"}],"version-history":[{"count":0,"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/posts\/6548\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/media\/6549"}],"wp:attachment":[{"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/media?parent=6548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/categories?post=6548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bad-drug.net\/wp-json\/wp\/v2\/tags?post=6548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}